Literature DB >> 18312155

Treatment options for non-motor symptoms in late-stage Parkinson's disease.

Miguel Coelho1, Joaquim Ferreira, Mário Rosa, Cristina Sampaio.   

Abstract

Late-stage Parkinson's disease is characterised by patients dependent on caregivers for their activities of daily living, even under the best levodopa benefit. Non-motor signs that overcome the well-known motor signs of Parkinson's disease dominate late-stage Parkinson's disease and few systematic data exist for the treatment of these signs. The objective of this study was to review the treatment options for Parkinson's disease dementia, psychosis, falls, bone fractures, joint and skeletal deformities, pain, orthostatic hypotension, gastrointestinal abnormalities and urological dysfunction in late-stage Parkinson's disease. The study analysed the available controlled clinical trials for the above medical conditions. When absent, data from case series and the authors' own experience was considered. Few controlled clinical trials specifically addressed late-stage Parkinson's disease as a target population. There is a need for therapeutic data on the symptoms that most afflict late-stage Parkinson's disease patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18312155     DOI: 10.1517/14656566.9.4.523

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  4 in total

Review 1.  Juvenile parkinsonism: epidemiology, diagnosis and treatment.

Authors:  Teri R Thomsen; Robert L Rodnitzky
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

Review 2.  Demystifying the Neuroprotective Role of Neuropeptides in Parkinson's Disease: A Newfangled and Eloquent Therapeutic Perspective.

Authors:  Tapan Behl; Piyush Madaan; Aayush Sehgal; Sukhbir Singh; Hafiz A Makeen; Mohammed Albratty; Hassan A Alhazmi; Abdulkarim M Meraya; Simona Bungau
Journal:  Int J Mol Sci       Date:  2022-04-20       Impact factor: 6.208

3.  Resource Utilization of Patients with Parkinson's Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study.

Authors:  Christopher Kruse; Sabrina Kretschmer; Anna Lipinski; Malte Verheyen; David Mengel; Monika Balzer-Geldsetzer; Stefan Lorenzl; Carmen Richinger; Christian Schmotz; Lars Tönges; Dirk Woitalla; Stephan Klebe; Anette Schrag; Richard Dodel
Journal:  Pharmacoeconomics       Date:  2021-03-19       Impact factor: 4.981

4.  Açai Berry Mitigates Parkinson's Disease Progression Showing Dopaminergic Neuroprotection via Nrf2-HO1 Pathways.

Authors:  Ramona D'Amico; Daniela Impellizzeri; Tiziana Genovese; Roberta Fusco; Alessio Filippo Peritore; Rosalia Crupi; Livia Interdonato; Gianluca Franco; Ylenia Marino; Alessia Arangia; Enrico Gugliandolo; Salvatore Cuzzocrea; Rosanna Di Paola; Rosalba Siracusa; Marika Cordaro
Journal:  Mol Neurobiol       Date:  2022-08-15       Impact factor: 5.682

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.